11.20

107.02% 5.79

Replimune Group Inc (REPL)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$5.41

Aprire:

$11.379

Volume 24 ore:

33.46M

Relative Volume:

5.78

Capitalizzazione di mercato:

$940.19M

Reddito:

Utile/perdita netta:

$-313.94M

Rapporto P/E:

-3.1945

EPS:

-3.506

Flusso di cassa netto:

$-284.57M

1 W Prestazione:

+15.46%

1M Prestazione:

+1.17%

6M Prestazione:

+59.32%

1 anno Prestazione:

+59.32%

Intervallo 1D:

$9.43

$12.50

Intervallo di 1 settimana:

$4.7648

$12.50

Portata 52W:

$1.50

$12.50

Replimune Group Inc Stock (REPL) Company Profile

Nome

Replimune Group Inc

Settore

Healthcare (1079)

Industria

Biotechnology (598)

Telefono

(781) 222-9600

Indirizzo

500 UNICORN PARK, WOBURN, MA

Dipendente

465

Cinguettio

@Replimune

Prossima data di guadagno

2026-08-06

Ultimi documenti SEC

REPL's Discussions on Twitter

Compare REPL vs VRTX, REGN, ARGX, RVMD, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
REPL Replimune Group Inc	11.20	724.45M	0	-313.94M	-284.57M	-3.506
VRTX Vertex Pharmaceuticals Inc	477.10	121.57B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	762.63	69.95B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	853.82	55.61B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	187.53	39.98B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	316.01	33.81B	5.76B	514.49M	1.10B	4.4813

Replimune Group Inc Stock (REPL) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-04-13	Downgrade	BMO Capital Markets	Market Perform → Underperform
2026-04-13	Downgrade	H.C. Wainwright	Buy → Sell
2026-04-13	Downgrade	JP Morgan	Neutral → Underweight
2026-04-13	Downgrade	Jefferies	Buy → Hold
2026-04-13	Downgrade	Leerink Partners	Outperform → Market Perform
2026-04-13	Downgrade	Wedbush	Outperform → Neutral
2026-04-10	Downgrade	Piper Sandler	Overweight → Neutral
2025-11-03	Aggiornamento	BMO Capital Markets	Underperform → Market Perform
2025-10-27	Aggiornamento	H.C. Wainwright	Neutral → Buy
2025-10-20	Aggiornamento	JP Morgan	Underweight → Neutral
2025-10-20	Aggiornamento	Leerink Partners	Market Perform → Outperform
2025-10-20	Aggiornamento	Piper Sandler	Neutral → Overweight
2025-10-20	Aggiornamento	Wedbush	Neutral → Outperform
2025-09-19	Downgrade	JP Morgan	Neutral → Underweight
2025-07-30	Aggiornamento	Cantor Fitzgerald	Neutral → Overweight
2025-07-23	Downgrade	BMO Capital Markets	Outperform → Underperform
2025-07-23	Downgrade	Barclays	Overweight → Equal Weight
2025-07-23	Downgrade	H.C. Wainwright	Buy → Neutral
2025-07-22	Downgrade	JP Morgan	Overweight → Neutral
2025-07-22	Downgrade	Leerink Partners	Outperform → Market Perform
2025-07-22	Downgrade	Piper Sandler	Overweight → Neutral
2025-07-22	Downgrade	Wedbush	Outperform → Neutral
2025-06-20	Iniziato	Cantor Fitzgerald	Overweight
2024-08-28	Iniziato	ROTH MKM	Buy
2023-04-17	Ripresa	Piper Sandler	Overweight
2021-11-19	Iniziato	Piper Sandler	Overweight
2021-10-15	Ripresa	BTIG Research	Buy
2020-11-17	Iniziato	BTIG Research	Buy
2020-11-02	Iniziato	Jefferies	Buy
2020-10-15	Aggiornamento	H.C. Wainwright	Neutral → Buy
2020-07-01	Downgrade	H.C. Wainwright	Buy → Neutral
2020-05-05	Iniziato	Barclays	Overweight
2019-09-04	Iniziato	ROTH Capital	Buy
2019-07-23	Iniziato	Chardan Capital Markets	Buy
2019-07-12	Aggiornamento	JP Morgan	Neutral → Overweight
2019-07-08	Iniziato	H.C. Wainwright	Buy
2019-04-25	Iniziato	Wedbush	Outperform
2019-01-23	Downgrade	JP Morgan	Overweight → Neutral
2018-08-14	Iniziato	JP Morgan	Overweight
2018-08-14	Iniziato	Leerink Partners	Outperform

Mostra tutto

Replimune Group Inc Borsa (REPL) Ultime notizie

Jul 28, 2026

Wedbush Weighs FDA Advisory Committee Vote on REPL's RP1 Amid Mi - GuruFocus

Jul 28, 2026

FDA Staff Raise Concerns On Replimune’s Skin Cancer Drug – REPL Stock Crashes 32% Today Ahead Of Advisory Meeting This Week - Yahoo Finance

Jul 28, 2026

US FDA staff cast doubt on Replimune cancer drug’s benefit; shares slide - 1470 & 100.3 WMBD

Jul 28, 2026

Replimune (REPL) Slumps As Losses Mount And Legal Scrutiny Grows - StocksToTrade

Jul 28, 2026

Replimune joins Capricor in post-briefing doc drop (REPL:NASDAQ) - Seeking Alpha

Jul 28, 2026

US FDA staff raise efficacy concerns on Replimune's skin cancer drug ahead of meeting - Reuters

Jul 28, 2026

Replimune stock tumbles 20% after FDA raises efficacy concerns By Investing.com - Investing.com Nigeria

Jul 28, 2026

Jul 27, 2026